Blenrep
Chemical Name | belantamab mafodotin |
Dosage Form | Injection; (Iintravenous; 100mg) |
Drug Class | Antineoplastics |
System | Blood |
Company | GlaxoSmithKline plc |
Approval Year | 2020 |
Indication
- For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.